Clinical Report: Lp(a) and Women's Long-Term Heart Risk

Overview

Revise to specify the types of major cardiovascular events and ensure alignment with the source.

Background

Understanding the relationship between lipoprotein(a) levels and cardiovascular risk is crucial, particularly in women who may have different risk profiles compared to men. This study provides valuable insights into how Lp(a) levels can serve as a marker for long-term cardiovascular risk, emphasizing the need for targeted screening and potential preventive measures.

Data Highlights

Key Findings

• Women with Lp(a) levels >30 mg/dL have a higher 30-year risk of major cardiovascular events.
• Those with Lp(a) ≥120 mg/dL have a 54% higher risk of major cardiovascular events compared to those with levels <10 mg/dL.
• Women above the 99th percentile (≥131 mg/dL) show a 74% higher risk of major cardiovascular events.
• Carriers of the rs3798220 minor allele have a 27% higher risk of major cardiovascular events.
• The findings may not apply to non-European populations and need confirmation in men.

Clinical Implications

Incorporate specific screening guidelines and mention potential therapies for high Lp(a) levels.

Conclusion

The findings underscore the importance of monitoring lipoprotein(a) levels in women to identify those at increased risk for cardiovascular events. This could lead to more personalized preventive care strategies.

References

1. Tybjærg Nordestgaard A., JAMA Cardiology, 2026 -- Thirty-Year Risk of Cardiovascular Disease Among Healthy Women According to Clinical Thresholds of Lipoprotein(a)
2. European Journal of Preventive Cardiology, 2026 -- Lipoprotein(a) and Its Association with Cardiovascular Risk: Recent Developments
3. ACC/AHA, 2026 -- ACC/AHA Issue Updated Guideline for Managing Lipids, Cholesterol
4. European Journal of Preventive Cardiology — Lipoprotein (a) and incident coronary heart disease in the community: impact of traditional cardiovascular risk factors
5. European Journal of Preventive Cardiology — The additive prognostic value of lipoprotein(a) for all-cause and cardiovascular mortality across the traditional cardiovascular risk continuum: analysis from NHANES III (1988–1994) with follow-up to 2019
6. European Journal of Preventive Cardiology — Lipoprotein(a) and its Role in Atherosclerotic Cardiovascular Disease: The Potential Influence of High-Sensitivity C-Reactive Protein and Future Directions
7. ACC/AHA Issue Updated Guideline for Managing Lipids, Cholesterol - American College of Cardiology
8. Thirty-Year Risk of Cardiovascular Disease Among Healthy Women According to Clinical Thresholds of Lipoprotein(a) | Cardiology | JAMA Cardiology | JAMA Network
9. Ionis statement on Novartis’ updated timing for Phase 3 pelacarsen data